Liquid Array Protein Assay Platform

描述（由申请人提供）：该项目的目的是开发和优化我们的新型颗粒基微阵列平台ArrayableESP，用于人类血清样品的高倍数（50至2000倍）蛋白质组学分析。esp是光学编码的微制造粒子，可以用磁力操纵。它们是在商业上可用的光刻设备上制造的，采用了从半导体工业借鉴的高效而坚固的技术。与现有的基于磁头的液体阵列平台相比，它们在成本吞吐量、可扩展性和灵活性方面具有显著优势。我们将在我们的平台上使用适配体，而不是抗体，这将消除对样品预标记/预处理的需要，并允许在蛋白质结合后进行均匀检测的平行方法。ArrayableESP平台与适体的结合有望提高分析的准确性，并简化工作流程。这些特性，再加上ArrayableESP平台提供的几乎无限的多路分析潜力，将提供一种比现有蛋白质组学分析技术具有显著优势的多路分析产品。ESP技术具有广泛的适用性，应该成为各种疾病状态的诊断、预后和表征的有价值的工具，包括癌症、心脏病、关节炎和炎症性疾病、肾脏疾病、肝脏疾病、过敏反应和传染病（如HIV）。

DESCRIPTION (provided by applicant): The aim of this project is to develop and optimize our novel particle-based microarray platform, ArrayableESP, for application to high multiplex (50- to 2000-plex) proteomic analysis of human serum samples. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. They are manufactured on commercially available photolithographic equipment using efficient and robust techniques borrowed from the semi-conductor industry. They have significant advantages in cost throughput, scalability, and flexibility over existing bead-based liquid array platforms. We will use aptamers, instead of antibodies, on our platform, which will eliminate the need for sample pre-labeling/pre-processing and allow for a parallel method of homogeneous detection following protein binding. The combination of the ArrayableESP platform with aptamers is expected to increase accuracy of analysis and result in a simplified workflow. Such attributes, in combination with the nearly unlimited multiplex potential offered by the ArrayableESP platform, will provide a multiplex product with significant advantages over currently available technologies for proteomic analysis. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: Efficient high multiplexed genomic analysis has been achieved by others. Analysis of the proteome is expected to be the next important component of biological analysis for improving human health. Current methods for multiplex proteomic analysis are either unable to perform greater than 30-plex analysis, or at high multiplex require processes that result in inaccurate analysis with inefficient workflows. We are developing a cost-effective technology for low to high multiplex proteomic analysis with significant advantages over current comparable technologies. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, and infectious diseases (e.g. HIV).